IP Library Granted Patent US 11,554,185
Granted Patent B2
US 11,554,185 · App. 16/236,193 · Granted Jan 17, 2023

Systems and methods for treating biological fluids

Inventors: Daniel Church (Danville, CA); Peter Bringmann (Concord, CA); Grace Castro (Martinez, CA); Thea Lu (Pleasant Hill, CA); Shelby Reinhardt (San Francisco, CA); Felicia Santa Maria (Bay Point, CA); Adonis Stassinopoulos (Dublin, CA)
Assignee: Cerus Corporation
A61L2/0047A01N1/0215A01N1/0294A61K31/37A61K41/17A61L2/0076A61L2/26A61M1/3683B01J19/123H01L25/0753A61L2/24A61L2202/11A61L2202/122A61L2202/14A61L2202/22A61M2202/0415A61M2202/0427
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,554,185
App. No.
16/236,193
Granted
Jan 17, 2023
Kind
B2
Abstract

Provided are systems and methods for treating a biological fluid, e.g., to inactivate pathogens.

Claims (59)

1. A system for treating a biological fluid, the system comprising:

a treatment chamber configured to receive a biological fluid;

one or more sensors configured to detect light in the treatment chamber;

a first array of light sources positioned to illuminate the biological fluid in the treatment chamber, wherein the first array of light sources comprises a first light source channel configured to emit ultraviolet light with a first peak wavelength of the first array of from about 315 nm to about 350 nm, and wherein the first light source channel comprises one or more light sources, each of which emits light having a full-width half-maximum (FWHM) spectral bandwidth of less than 20 nanometers; and

control circuitry, wherein the control circuitry comprises:

a memory;

one or more processors; and

one or more programs, wherein the one or more programs are stored in the memory and configured to be executed by the one or more processors, the one or more programs when executed by the one or more processors cause the processor to:

illuminate a biological fluid in admixture with a pathogen inactivation compound by controlling the first array of light sources to transmit light for a duration and at an intensity sufficient to inactivate a pathogen in the biological fluid when present.

2. The system of claim 1 , wherein the first peak wavelength of the first array is from about 315 nm to about 335 nm.

3. The system of claim 1 , wherein the first peak wavelength of the first array is from about 330 nm to about 350 nm.

4. The system of claim 1 , wherein the first peak wavelength of the first array is the average peak wavelength of the one or more light sources of the first light source channel.

5. The system of claim 1 , wherein the one or more light sources of the first light source channel comprises one or more light emitting diodes (LEDs).

6. The system of claim 1 , wherein the first array of light sources further comprises a second light source channel configured to emit light with a second peak wavelength of the first array, wherein the second light source channel comprises one or more light sources, each of which emits light having a full-width half-maximum (FWHM) spectral bandwidth of less than 20 nanometers, and wherein the second peak wavelength of the first array differs from the first peak wavelength of the first array by at least 5 nanometers.

7. The system of claim 6 , wherein the second peak wavelength of the first array is in an ultraviolet A, ultraviolet B, or ultraviolet C spectrum.

8. The system of claim 1 , wherein light sources of the first array of light sources are positioned in a non-uniform distribution on the array.

9. The system of claim 1 , wherein the first array of light sources comprises two or more panels of light sources.

10. The system of claim 1 , further comprising a first platform positioned in the treatment chamber, the first platform configured to carry the biological fluid.

11. The system of claim 10 , wherein the first platform and the first array of light sources are configured to translate relative to each other to vary a distance between the first array of light sources and the first platform.

12. The system of claim 1 , further comprising a barrier positioned in the treatment chamber between the first array of light sources and the biological fluid.

13. The system of claim 12 , wherein one or more of the one or more sensors are affixed to or positioned in the barrier positioned in the treatment chamber between the first array of light sources and the biological fluid.

14. The system of claim 1 , wherein the first array comprises:

a first region of light sources configured to illuminate the biological fluid as a first illuminated biological fluid in the treatment chamber and a second region of light sources configured to illuminate a second illuminated biological fluid in the treatment chamber.

15. The system of claim 1 , wherein the control circuitry is configured to adjust or set an intensity of or a duration of emission of light from each light source of the first array of light sources.

16. The system of claim 1 , further comprising one or more sensors configured to detect the presence of a biological fluid within the treatment chamber.

17. The system of claim 1 , further comprising a second array of light sources facing an opposite direction as the first array of light sources, wherein the second array of light sources comprises a first light source channel configured to emit light of a first peak wavelength of the second array, and wherein the first light source channel of the second array comprises one or more light sources, each of which emits light having a full-width half-maximum (FWHM) spectral bandwidth of less than 20 nanometers.

18. The system of claim 17 , wherein the first peak wavelength of the second array is substantially the same as the first peak wavelength of the first array.

19. The system of claim 17 , wherein the second array of light sources comprises a second light source channel configured to emit light of a second peak wavelength of the second array, wherein the second light source channel of the second array comprises one or more light sources, each of which emits light having a full-width half-maximum (FWHM) spectral bandwidth of less than 20 nanometers, and wherein the second peak wavelength of the second array differs from the first peak wavelength of the second array by at least 5 nanometers.

20. The system of claim 1 , further comprising a second array of light sources facing a same direction as the first array of light sources, wherein the second array of light sources comprises a first light source channel configured to emit light of a first peak wavelength of the second array, and wherein the first array of light sources and the second array of light sources define a first region between the first array of light sources and the second array of light sources, and wherein first light source channel of the second array comprises one or more light sources, each of which emits light having a full-width half-maximum (FWHM) spectral bandwidth of less than 20 nanometers.

21. The system of claim 17 , further comprising a first platform positioned in the treatment chamber between the first array of light sources and the second array of light sources, the first platform configured to carry the biological fluid.

22. The system of claim 20 , further comprising:

a first platform positioned in the treatment chamber in the first region, the first platform configured to carry the biological fluid as a first carried biological fluid; and

a second platform positioned in the treatment chamber outside the first region, the second platform configured to carry a second carried biological fluid, wherein the second array of light sources faces the second platform.

23. The system of claim 17 , further comprising a barrier positioned in the treatment chamber between the second array of light sources and a biological fluid.

24. The system of claim 23 , wherein one or more of the one or more sensors are affixed to or positioned in the barrier positioned in the treatment chamber between the second array of light sources and a biological fluid.

25. The system of claim 17 , further comprising control circuitry configured to adjust or set an intensity of or a duration of emission of light from each light source of the second array of light sources.

26. The system of claim 1 , wherein the control circuitry is configured to:

a) determine a set of characteristics of the biological fluid;

b) determine a treatment profile based on the set of characteristics of the biological fluid;

c) adjust or set a set of parameters of the treatment chamber in accordance with the treatment profile; and

d) illuminate the biological fluid in accordance with the treatment profile.

27. The system of claim 1 , wherein the system is configured to illuminate the biological fluid in admixture with a photoactive pathogen inactivation compound for a duration and at an intensity sufficient to inactivate at least 1 log of a pathogen in the biological fluid when present, and wherein the biological fluid after illuminating is suitable for infusion into a subject without further processing to remove residual photoactive pathogen inactivation compound or photoproduct(s) thereof.

28. The system of claim 1 , wherein the system is configured to illuminate the biological fluid in admixture with a photoactive pathogen inactivation compound for a duration and at an intensity sufficient to inactivate at least 1 log of a pathogen in the biological fluid when present, and wherein the biological fluid comprises 5 μM or less of photoactive pathogen inactivation compound after illuminating.

29. The system of claim 1 , wherein the system is configured to illuminate the biological fluid in admixture with a photoactive pathogen inactivation compound for a duration and at an intensity sufficient to inactivate at least 4 log of a pathogen in the biological fluid when present.

30. The system of claim 1 , wherein the biological fluid comprises a blood product.

31. The system of claim 1 , wherein the pathogen inactivation compound is a psoralen.

32. The system of claim 31 , wherein the pathogen inactivation compound is amotosalen.

33. The system of claim 6 , wherein the second light source channel comprises one or more LEDs.

34. The system of claim 1 , wherein the first array is configured such that light sources of the first array illuminate the biological fluid in the treatment chamber with less than 25% variance in irradiance across a surface of the biological fluid facing the first array.

35. The system of claim 10 , wherein the first platform is slidably moveable for introducing and removing the biological fluid into and out of the treatment chamber.

36. The system of claim 10 , wherein the first platform is configured to separately hold at least a first container with the biological fluid as a first biological fluid and a second container with a second biological fluid.

37. The system of claim 12 , wherein the barrier positioned in the treatment chamber between the first array of light sources and the biological fluid is transparent to light with a wavelength within 30 nm of the first peak wavelength of the first array.

38. The system of claim 15 , wherein the control circuitry is configured to adjust or set the intensity of or the duration of emission of light from each light source of the first array of light sources based at least in part on a first set of parameters detected by at least one sensor of the one or more sensors configured to detect light.

39. The system of claim 17 , wherein the first array of light sources and the second array of light sources are configured to translate relative to each other to vary a distance between the first array of light sources and the second array of light sources.

40. The system of claim 23 , wherein the barrier positioned in the treatment chamber between the second array of light sources and a biological fluid is transparent to light with a wavelength within 30 nm of the first peak wavelength of the first array.

41. The system of claim 25 , wherein the control circuitry is configured to adjust or set the intensity of or the duration of emission of light from each light source of the second array of light sources based at least in part on a first set of parameters detected by at least one sensor of the one or more sensors configured to detect light.

42. The system of claim 1 , wherein the system is configured to illuminate the biological fluid in admixture with a pathogen inactivation compound for a duration and at an intensity sufficient to reduce the concentration of the pathogen inactivation compound in admixture with the biological fluid by at least 3-fold relative to the concentration of pathogen inactivation compound in admixture with the biological fluid prior to illuminating.

43. The system of claim 1 , wherein the biological fluid comprises a plasma composition.

44. The system of claim 1 , wherein the biological fluid comprises a platelet composition.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded May 20, 2026
From: MIDCAP FUNDING IV TRUST
To: CERUS CORPORATION
Reel/Frame 075583/0598 →
RELEASE OF SECURITY INTEREST Recorded May 20, 2026
From: MIDCAP FINANCIAL TRUST
To: CERUS CORPORATION
Reel/Frame 075610/0621 →
AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT (REVOLVING LOAN) Recorded Aug 29, 2025
From: CERUS CORPORATION
To: MIDCAP FUNDING IV TRUST
Reel/Frame 072727/0854 →
AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT (TERM LOAN) Recorded Aug 29, 2025
From: CERUS CORPORATION
To: MIDCAP FINANCIAL TRUST
Reel/Frame 072727/0928 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2022
From: CHURCH, DANIEL; BRINGMANN, PETER; CASTRO, GRACE; LU, THEA; REINHARDT, SHELBY; MARIA, FELICIA SANTA; STASSINOPOULOS, ADONIS
To: CERUS CORPORATION
Reel/Frame 061503/0299 →
Continuity (2)
Provisional Application 62612314 · Dec 29, 2017
Related Publication 20190209718A1 · Jul 11, 2019
Cited By (4)
US 12,214,092 US 12,343,436 US 12,514,944 US 12,558,442